Galectin Therapeutics' Q3 2026 net loss narrows 56% to $3.6 million
GALT•Galectin Therapeutics reported a Q3 2026 net loss of $3.6 million, down 56% versus the quarter ended June 30, 2025. Cash was $11.7 million at September 30, and management expects funding to cover planned operations through June 2027.




